Can-Fite BioPharma Ltd.
CANF- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001536196
No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Can-Fite BioPharma Ltd. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 13 | 12 | −1 |
| Shares | 381.5K | 505.7K | +124.2K (+32.6%) |
| Value | $472.3K | $464.7K | −$7.59K (−1.6%) |
New holders (2)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 56,322 | $52.0K | 0.00% |
| Susquehanna International Group, LLP | 46,670 | $43.0K | 0.00% |
Sold out (3)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Citadel Advisors LLC | 11,333 | $14.0K |
| Wells Fargo & Company | 1,500 | $2.00K |
| Bank of America Corp | 366 | $0 |